Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol

Nature Structural & Molecular Biology volume 24, pages 785–786 (2017)Cite this article

Subjects

PCSK9 enhances LDL cholesterol (LDL-c) levels by escorting the liver LDL receptor (LDLR) to endosomes and lysosomes for degradation. PCSK9 monoclonal antibodies and RNA-antisense formulations are effective in reducing LDL cholesterol in patients. The recent structural identification of a novel pocket in PCSK9 paves the way to the future development of orally active small-molecule hypocholesterolemic drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Inhibition of the PCSK9-induced LDLR degradation.

References

  1. Goldstein, J.L. & Brown, M.S. Arterioscler. Thromb. Vasc. Biol. 29, 431–438 (2009).

    Article  CAS  Google Scholar 

  2. LaRosa, J.C. et al. N. Engl. J. Med. 352, 1425–1435 (2005).

    Article  CAS  Google Scholar 

  3. Besseling, J., van Capelleveen, J., Kastelein, J.J. & Hovingh, G.K. Drugs 73, 293–301 (2013).

    Article  CAS  Google Scholar 

  4. Seidah, N.G. et al. Proc. Natl. Acad. Sci. USA 100, 928–933 (2003).

    Article  CAS  Google Scholar 

  5. Seidah, N.G. & Prat, A. Nat. Rev. Drug Discov. 11, 367–383 (2012).

    Article  CAS  Google Scholar 

  6. Abifadel, M. et al. Nat. Genet. 34, 154–156 (2003).

    Article  CAS  Google Scholar 

  7. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr. & Hobbs, H.H. N. Engl. J. Med. 354, 1264–1272 (2006).

    Article  CAS  Google Scholar 

  8. Maxwell, K.N. & Breslow, J.L. Proc. Natl. Acad. Sci. USA 101, 7100–7105 (2004).

    Article  CAS  Google Scholar 

  9. Zhang, D.W. et al. J. Biol. Chem. 282, 18602–18612 (2007).

    Article  CAS  Google Scholar 

  10. Cunningham, D. et al. Nat. Struct. Mol. Biol. 14, 413–419 (2007).

    Article  CAS  Google Scholar 

  11. Lo Surdo, P. et al. EMBO Rep. 12, 1300–1305 (2011).

    Article  CAS  Google Scholar 

  12. Zhang, D.W., Garuti, R., Tang, W.J., Cohen, J.C. & Hobbs, H.H. Proc. Natl. Acad. Sci. USA 105, 13045–13050 (2008).

    Article  CAS  Google Scholar 

  13. Seidah, N.G., Abifadel, M., Prost, S., Boileau, C. & Prat, A. Pharmacol. Rev. 69, 33–52 (2017).

    Article  CAS  Google Scholar 

  14. Stein, E.A. et al. Eur. Heart J. 35, 2249–2259 (2014).

    Article  CAS  Google Scholar 

  15. Stein, E.A. Curr. Opin. Endocrinol. Diabetes Obes. 23, 97–105 (2016).

    Article  CAS  Google Scholar 

  16. Sabatine, M.S. et al. N. Engl. J. Med. 376, 1713–1722 (2017).

    Article  CAS  Google Scholar 

  17. Fitzgerald, K. et al. Lancet 383, 60–68 (2014).

    Article  CAS  Google Scholar 

  18. Fitzgerald, K. et al. N. Engl. J. Med. 376, 41–51 (2017).

    Article  CAS  Google Scholar 

  19. Kwon, H.J., Lagace, T.A., McNutt, M.C., Horton, J.D. & Deisenhofer, J. Proc. Natl. Acad. Sci. USA 105, 1820–1825 (2008).

    Article  CAS  Google Scholar 

  20. Zhang, Y. et al. Nat. Struct. Mol. Biol. 24, 848–856 (2017).

    Article  CAS  Google Scholar 

  21. Zhang, Y. et al. J. Biol. Chem. 289, 942–955 (2014).

    Article  CAS  Google Scholar 

  22. Cameron, J. et al. Hum. Mol. Genet. 15, 1551–1558 (2006).

    Article  CAS  Google Scholar 

  23. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N. & Seidah, N.G. J. Biol. Chem. 281, 30561–30572 (2006).

    Article  CAS  Google Scholar 

  24. Schroeder, K.M. et al. J. Lipid Res. 56, 2124–2132 (2015).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the CIHR grants Foundation Scheme #148363, a Canada Research Chair #231335, and a Fondation Leducq grant #13CVD03. The author acknowledges the expert contribution of E. Girard.

Author information

Authors and Affiliations

  1. the Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada

    Nabil G Seidah

Authors
  1. Nabil G Seidah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil G Seidah.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seidah, N. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol. Nat Struct Mol Biol 24, 785–786 (2017). https://doi.org/10.1038/nsmb.3471

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nsmb.3471

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research